
News|Articles|January 1, 2012
FDA Pipeline Preview, January 2012 (Alexza Pharmaceuticals, Pfizer, Celladon, Vertex, Avedro)
Recent FDA action (through December 2011) related to staccato loxapine, axitinib, mydicar, kalydeco, riboflavin ophthalmic solution, minocycline hydrochloride
Advertisement
Recommendations for approval
Fast-track designation
Priority review
• First-time generic approval
MInocycline hydrocholride extended-release tablets in 45-mg, 55-mg, 90-mg, and 135-mg strengths (equiv to Solodyn)
LUPIN PHARMACEUTICALS
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
3
Biosimilar competition could surpass IRA-negotiated savings by year three
4
Midlife influenza vaccine not associated with increased risk of Parkinson’s disease, study shows
5





















































